Advanced Cell Technology (ACTC), a biotechnology company, engages in the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. It primarily focuses on cellular reprogramming, reduced complexity program, and stem cell differentiation research programs.

The company develops adult stem cell-based products that are specifically targeted at therapies for heart and other cardiovascular diseases. Its stem cell-based therapy would provide treatment for an array of chronic degenerative diseases and in the regenerative repair of acute disease, such as trauma, infarction, and burns.

It also has a joint venture agreement with CHA Biotech Co. Limited to develop human blood cells and other clinical therapies based on the company’s proprietary hemangioblast cell technology.

The company is headquartered in Worcester, Massachusetts.

Information provided by Capital IQ.

http://www.advancedcell.com

Track Four - 4:30 pm